FAM98C Inhibitors
FAM98C inhibitors encompass a range of compounds that influence various cellular signaling pathways and processes. LY294002 and Wortmannin are two such inhibitors that target the PI3K/AKT signaling pathway. By inhibiting PI3K, these compounds prevent the phosphorylation and subsequent activation of AKT, leading to a decrease in downstream signaling activities that may involve FAM98C. This reduced signaling can result in lower FAM98C activity if FAM98C's function is reliant on signals propagated through the AKT pathway.
In addition to the PI3K/AKT pathway, other compounds such as PD98059 and U0126 target the MAPK/ERK pathway by specifically inhibiting MEK1/2. This inhibition results in less activation of ERK, a kinase that could phosphorylate and regulate FAM98C.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that impairs the activation of the MAPK/ERK pathway. If FAM98C's activity is contingent on signals from this pathway, particularly in cell proliferation or differentiation, U0126 would result in decreased FAM98C activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR that can inhibit both mTORC1 and mTORC2 complexes. The mTOR pathway is critical for cell growth and survival, and inhibition by AZD8055 would decrease FAM98C activity if it is linked to this pathway. | ||||||